• SB203580: Translating p38 MAPK Insight into Action

  2026-08-13

  A translational framework for using SB203580 to test p38 MAPK-dependent inflammation, connect oral–pulmonary disease mechanisms, and design more decisive pathway-validation studies.

• Boc-D-FMK Workflows for Apoptosis Research

  2026-08-13

  Boc-D-FMK provides a practical way to suppress activated-caspase activity while separating apoptosis from inflammatory and fibrotic readouts. This guide translates product specifications into reproducible cell and animal workflows, with assay controls inspired by a hepatic stellate-cell fibrosis study.

• HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation

  2026-08-12

  The reference study identifies an epigenetic mechanism by which EBV LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It shows that HDAC inhibition restores CEBPA expression and reverses this state in xenograft models, providing a mechanistic rationale for differentiation-oriented treatment of a solid tumor.

• Caspase-8 Inhibition and Shared Caspase Specificity

  2026-08-12

  Bourne and colleagues developed an LESD-based peptide inhibitor derived from the IL-18 cleavage sequence that preferentially inhibits caspase-8, while revealing unexpected overlap between inflammatory and apoptotic initiator caspases. Their standardized comparisons also showed that VX-765, commonly used to inhibit caspases-1 and -4, inhibits caspase-8 at micromolar potency, an important consideration for interpreting caspase-targeted experiments.

• JNK-IN-7 for Reliable Apoptosis Assays

  2026-08-11

  Learn how JNK-IN-7 (SKU A3519) can improve mechanistic interpretation of cell viability, proliferation, and apoptosis experiments by selectively inhibiting JNK1, JNK2, and JNK3. This scenario-based guide covers assay design, formulation, controls, data interpretation, and practical product selection.

• GW 6471: Decoding PPARα in Metabolic Toxicology

  2026-08-11

  GW 6471 offers a practical route to test whether PPARα activity is causal in lipid disruption, hepatotoxicity, and broader metabolic phenotypes. By connecting zebrafish PFHxS evidence with translational experimental design, this article shows how pharmacological antagonism can strengthen cellular metabolism research without overstating model-to-clinic conclusions.

• Oridonin Protects Bone via MAPK/NF-κB and BMP-2/RUNX2

  2026-08-10

  The reference study identifies oridonin as a dual-action candidate that limits thioacetamide-induced osteoclastogenesis while restoring osteoblast-related differentiation. Its results connect suppression of MAPK/NF-κB activity and oxidative signaling with activation of the BMP-2/RUNX2 osteogenic axis, offering a mechanistic framework for studying bone loss associated with inflammatory and toxicant stress.

• Fumagillin and Soft Tunic Syndrome Parasite Control

  2026-08-09

  The reference study systematically compared 20 compounds against Azumiobodo hoyamushi, the protozoan associated with soft tunic syndrome in cultured Halocynthia roretzi. Fumagillin showed moderate in vitro activity, while formalin and chlorine dioxide produced the clearest reduction of parasite cells in experimentally infected ascidians, providing a useful framework for screening and validating aquatic disease-control treatments.

• VX-765 for Caspase-1 Assays

  2026-08-08

  VX-765 helps separate caspase-1-driven inflammation and pyroptosis from transcription-linked apoptosis. This workflow-focused guide covers dosing, cytokine readouts, biochemical confirmation, and troubleshooting for macrophage, lymphocyte, and translational inflammation studies.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1

  2026-08-07

  PYR-41 enables upstream interrogation of ubiquitin-dependent protein turnover, NF-κB signaling, and inflammatory phenotypes in cell and animal research. Its strongest use-case is mechanistic pathway dissection, provided that solubility, exposure timing, viability, and off-target effects are controlled.

• Human iPSC Sensory Neuron Model Validates HSV-1 Latency and

  2026-08-07

  The reference study introduces a scalable system for differentiating human inducible pluripotent stem cells (hiPSCs) into functional sensory neurons, enabling robust modeling of herpes simplex virus 1 (HSV-1) latent infection and reactivation. This innovation addresses a critical gap by providing a human neuronal platform for mechanistic studies of HSV-1 latency, with implications for antiviral research and therapeutic development.

• JNK-IN-7: Unraveling Apoptotic Pathways for Translational Im

  2026-08-06

  This thought-leadership article explores how the selective JNK inhibitor JNK-IN-7 enables translational researchers to dissect apoptosis and innate immune signaling pathways, drawing on recent breakthroughs in Candida krusei-induced mammary cell apoptosis. Mechanistic insight, protocol guidance, and a forward-looking perspective are integrated to empower advanced MAPK pathway research.

• TSPAN18–STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-08-06

  Zhou et al. (2023) identify TSPAN18 as a key regulator of bone metastasis in prostate cancer by protecting STIM1 from TRIM32-mediated degradation, thus promoting calcium signaling and metastatic progression. This mechanistic insight opens new avenues for targeting bone metastasis in hormone-responsive cancers.

• SB 202190: Precision p38 MAPK Inhibition for Translational D

  2026-08-05

  SB 202190 (FHPI), a highly selective p38 MAP kinase inhibitor, is transforming translational research in inflammation, cancer, and neuroprotection. This thought-leadership article unpacks the mechanistic rationale, evidence, and strategic deployment of SB202190, building on recent MAPK/NF-κB pathway insights and offering actionable guidance for researchers seeking reproducibility and clinical relevance.

• Network Meta-Analysis: Azilsartan Medoxomil in Hypertension

  2026-08-05

  A systematic literature review and network meta-analysis compared azilsartan medoxomil (TAK 491) with other antihypertensives, finding that 80 mg azilsartan medoxomil had the highest probability of being most effective in reducing both systolic and diastolic blood pressure among mild-to-moderate hypertensive patients. These findings highlight azilsartan medoxomil’s potential for future essential hypertension treatment research and inform comparative efficacy studies.

8612 records 4/575 page Previous Next 12345 下5页 Last page